Multiple Myeloma Coverage from Every Angle

Prashant Kapoor, MD, and Shaji Kumar, MD, on Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma

Posted: Tuesday, June 16, 2020

Prashant Kapoor, MD, and Shaji Kumar, MD, both of the Mayo Clinic, discuss initial results of the phase III BOSTON study—the first trial to evaluate the clinical benefit of selinexor, bortezomib, and dexamethasone for relapsed or refractory multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.